20 December 2018
Scanfil Plc., a Global Contract Manufacturer and Systems Supplier, has signed an agreement with Profound Medical Corp., a medical technology company focused on a therapeutics platform that provides the precision of real-time Magnetic Resonance Imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue.
Scanfil was selected due to its broad service offering and its capability to serve the customer throughout the whole life-cycle of the product. Scanfil will be part of making Profound’s revolutionary new cancer treatment equipment, which combines MRI and ultrasound for better and more precise treatment.
“Securing a reliable and experienced manufacturer is crucial as we expect interest in, and adoption of, our technology to grow in 2019 and beyond,” said Arun Menawat, Profound’s CEO. “We are looking forward to working with Scanfil as we continue to pursue growth opportunities for our products, which we believe could fulfill unmet needs of doctors and patients alike.”
“I am happy that Profound Medical selected us to be their long-term partner. The company is very interesting, and their products are extremely innovative. We were selected due to our vertical integration service concept and capability to master material management, electronics and sheet metal manufacturing, final integration, testing, etc. This is again a good example that our strategy in the contract manufacturing market is right for us and it works”, says Timo Sonninen, Vice President, Sales.
Scanfil has over 40 years of successful experience in serving global companies within, e.g., MedTech& Life Science & Environment, Energy & Automation, Communication and Urban Applications.
Vice President, Sales
About Profound Medical Corp.
Profound is developing and commercializing therapeutic platforms that combine the power of real-time magnetic resonance (MR) imaging and non-invasive ultrasound ablation. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate disease (localized prostate cancer and benign prostatic hyperplasia), uterine fibroids, and bone metastases. Profound mission is to “profoundly” change the standard of care whereby clinicians can confidently ablate tissue with precision, and patients can access safe and effective treatment options and quickly return to their daily lives.
Profound’s novel TULSA-PRO® system combines real-time MR imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. TULSA-PRO® is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO® is CE marked and is undergoing a pilot commercial launch in key European and other CE mark jurisdictions. Profound is also sponsoring a multicenter, prospective U.S. Food and Drug Administration (FDA)-registered clinical trial, TACT, which if successful, is expected to support its application to the FDA for clearance to market TULSA-PRO® in the United States.
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that combines real-time MR imaging and thermometry with thermal ultrasound to enable precise and incision-free ablation of diseased tissue. Sonalleve® is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The technology was also recently approved by the Chinese Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve®, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy, where the technology has been shown to have clinical application.
Scanfil is an international contract manufacturer and system supplier for the electronics industry with 40 years of experience in demanding contract manufacturing. Scanfil provides its customers with an extensive array of services, ranging from product design to product manufacturing, material procurement and logistics solutions. Vertically integrated production and a comprehensive supply chain are the foundation of Scanfil’s competitive advantages: speed, flexibility and reliability.
Typical Scanfil products include mobile and communications network devices, automation system modules, frequency converters, lift control systems, analysers, various slot and vending machines, and devices related to medical technology and meteorology. Scanfil services are used by numerous international automation, energy, IT and health service providers, as well as companies operating in the field of urbanisation. Scanfil’s network of factories consists of 10 production units in Europe, Asia and North America. The total number of employees is about 3,400.
Due to legal restrictions, the information on this part of the website is not directed at or accessible to certain persons. We kindly ask you to review the following information and provide the following confirmation each time you wish to access this part of the website. Please note that the terms set out below may be altered or updated and therefore it is important that you review them each time you visit this website.
On 25 May 2015, Scanfil Oyj announced a cash offer to the shareholders in PartnerTech AB regarding acquisition of all the shares in PartnerTech AB (the “Offer”).
The Offer is not being made in any jurisdictions where the Offer or approval of an acceptance of the Offer cannot be made in accordance with laws and regulations in these jurisdictions or where acceptance or ap-proval of an acceptance of the Offer requires additional offer documents, registration or other measures than those required under Swedish law, except in the event of applicable exemptions.
The Offer is not being made to persons whose participation in the Offer requires that any additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish law. Documentation relating to the Offer must not be mailed, sent or otherwise distributed to, into or in any country in which the distribution or offering would require any additional measures required to be taken by any law or regulation in such country or that would be in conflict with any law or regulation in such country. Any such action will not be permitted or sanctioned by Scanfil Oyj. Any attempt to accept the Offer in direct or indirect violation of the abovementioned restrictions may be disre-garded.
The Offer is not being made, directly or indirectly, in or into Australia, Hong Kong, Japan, New Zealand, South Africa or the United States or in or into any other jurisdiction in which the distribution or acceptance of the Offer would not be made in compliance with the laws of such jurisdiction or where the acceptance or approval of an acceptance of the offer requires additional offer documents, registration or other measures than those required under Swedish law (together, the "Restricted Jurisdictions") by use of mail or any other means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, tele-phone and the Internet) of interstate or foreign commerce, or of any facility of national security exchange, of the Restricted Jurisdictions, and the Offer cannot be accepted by any such use, means, instrumentality or facility of, or from within, the Restricted Jurisdictions.
Accordingly, this website should not be accessed from, and any documentation relating to the Offer is not being and should not be sent, mailed or otherwise distributed, forwarded or sent into the Restricted Juris-dictions. The offer document, the acceptance form and any documentation related to the Offer will not be sent, and must not be sent, to shareholders with registered addresses in the Restricted Jurisdictions. Banks, brokers and other institutions holding nominee-registered shares on behalf of persons in the Restricted Jurisdictions may not forward the offer documents or any documentation related to the Offer, or otherwise make the Offer available, to such persons.
By accepting these conditions, I confirm that I have read the information, the conditions and the instructions on this website and that I accept to be bound by them and that I am not a resident of, nor located in Australia, Hong Kong, Japan, New Zealand, South Africa or the United States or any other Restricted Juris-diction.
You may refuse to accept cookies from our website and delete existing cookies by selecting the appropriate settings on your browser. If you wish to do so, please refer to your browser’s user guide to find out how to control cookies by adjusting your browser’s preferences.
Full Privacy notice for our website visitors can be found here: http://www.scanfil.com/privacy.html.